Akoya Biosciences, Inc.

#News: We are excited to announce our acquisition of Akoya Biosciences, Inc. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. This is an important step forward for our mission of early disease detection and will accelerate scientific discoveries and improve patient outcomes. Read more information and cautionary statements here: https://lnkd.in/eyYkVF9t

🚀 Exciting News from Weizmann Institute of Science! 🚀 ❗ We’re thrilled to announce the installation of the first Akoya Biosciences, Inc. PhenoImager HT system in Israel at the Weizmann Institute of Science, Department of Veterinary Resources, led by Liat Fellus Alyagor, Head of the Immunohistochemistry Unit. The PhenoImager HT is a cutting-edge spectral slide scanning platform with unmatched imaging capabilities. It can unmix up to 9 fluorescent channels and add autofluorescence as a separate data channel! Additionally, HT can process up to 80 slides at once, offering exceptional throughput and precision. When paired with the Leica BOND RXm system, this combination creates a powerful platform for generating high volumes of data, providing deeper insights into both research and clinical applications. 📸 We’re especially excited to share an image captured in the lab of Prof. Itay Tirosh. This image was taken using the PhenoImager HT’s spectral scanning capabilities and shows PDX model of human PDAC tumors stained with mesenchymal and epithelial markers for tumor type phenotyping. “The Phenoimager HT significantly upgrades our work capacity, allows fast and easy multiplex imaging and together with the BOND RXm generates the perfect pipeline for OPAL multiplex staining.” – says Dr. Alyagor. This milestone marks a significant step forward in scientific discovery and biomedical research. We can’t wait to see the impact it will have! 🔬 Looking forward to the innovations and collaborations ahead! Salem Sirhan, M.Sc Rhenium Group

We will be at the upcoming annual J.P. Morgan Healthcare Conference in San Francisco, CA, from January 13–16, 2025! 🎉 Join us to discuss how Akoya is revolutionizing spatial proteomics and shaping the future of precision medicine. 📅 Connect with our team to learn more: Brian McKelligon, Johnny Ek, Pascal Bamford, Niro Ramachandran, Mark Landers, Priyam Shah, and Sambhav Dave Don’t hesitate to reach out to schedule a meeting or say hello! #Akoya #TheSpatialBiologyCompany #SpatialProteomics #JPM2025 #HealthcareInnovation #PrecisionMedicine

What it is: The Akoya Biosciences PhenoCycler-Fusion 1.0 instrument When it was acquired: October 2023 Where it is: Jimmy Fund Building, 2nd Floor What it does: This microscopic imaging system enables pathologists to see up to 100 molecular biomarkers across every cell in a tumor sample on a single slide, letting them visualize which molecules are in each cell and where they are across the entire tissue sample. This wealth of information reveals how the tissue is organized and provides a nuanced understanding to better diagnose and treat the disease. How it works: Research scientist Namrata Singh, PhD, uses the instrument's microfluidic system to apply a cocktail of up to 40 antibodies to a tissue sample slide. Each antibody binds to an antigen that is a unique portion of a biomarker of interest. She then uses the system to add antibody-specific fluorescent color-coded reporters, which glow with a distinct color to signal the presence of a particular biomarker. Using the system, these signals are revealed and imaged. The antibodies and reporters are then removed by the system in preparation for another cocktail. During imaging, the slide lights up with fluorescent colors, indicating the presence and location of the biomarkers. Singh can switch signals on and off, for instance, to focus on immune biomarkers or examine biomarkers that indicate a specific type, stage, or feature of the cancer. “When I first saw the Phenocycler images, I felt so emotional,” says Singh. “It’s just... I’m having goosebumps right now. You can clearly see not only the tumor but also the tumor microenvironment and how the disease is behaving.” What it is used for: Traditional methods for revealing biomarkers can only reveal two or three at a time. This system can show up to 100, which enables researchers to learn more about how cancer and its surrounding tissues interact with and respond to treatments. Special services for scientists: Singh uses the instrument to support researchers who want to learn more about tissue samples they've collected as part of a study. She can help researchers create custom antibodies to look at markers that have not been studied before. Fun fact: The substances used to create the slide stain cocktails are stored in what Singh calls her “deli fridge” because it looks like a fridge of sodas in a delicatessen.

🚨 𝐓𝐨𝐝𝐚𝐲 𝐢𝐬 𝐭𝐡𝐞 𝐋𝐀𝐒𝐓 𝐝𝐚𝐲 𝐭𝐨 𝐚𝐩𝐩𝐥𝐲!  🚨 Don’t miss your chance to take part in the 𝐈𝐎𝟔𝟎 𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐎𝐦𝐢𝐜𝐬 𝐆𝐫𝐚𝐧𝐭 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 and advance your research with cutting-edge 𝐬𝐩𝐚𝐭𝐢𝐚𝐥 𝐩𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 on the 𝐏𝐡𝐞𝐧𝐨𝐂𝐲𝐜𝐥𝐞𝐫®-𝐅𝐮𝐬𝐢𝐨𝐧 𝟐.𝟎 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦. Apply now to unlock a 60-marker spatial phenotyping dataset and collaborate with Akoya experts to push the boundaries of your genomics and transcriptomics studies. 👉 Apply Here: https://lnkd.in/eHJzupXd ⏳ Applications close TODAY, December 13, 2024!

Last week at #Multiomics2024 in Brisbane, we had the opportunity to re-unite with the researchers from the spatial community and hear from Niro Ramachandran on Akoya’s exciting new product launch including IO-60 panel and our clinical vision in the coming years. What a fantastic conference led by Arutha Kulasinghe! We even hosted a round-the-table discussion amongst our PhenoCycler-Fusion users from Australia to foster collaboration and strengthen the largest spatial proteomics community in the country. #spatialbiology #akoyabiosciences #geneworks #multiomics2024 #spatialproteomicscommunity

𝐓𝐡𝐞 𝐈𝐎𝟔𝟎 𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐎𝐦𝐢𝐜𝐬 𝐆𝐫𝐚𝐧𝐭 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 – 𝟐 𝐃𝐚𝐲𝐬 𝐋𝐞𝐟𝐭 𝐭𝐨 𝐀𝐩𝐩𝐥𝐲!  We’re thrilled to offer this game-changing opportunity to elevate your research with cutting-edge spatial proteomics on the PhenoCycler®-Fusion 2.0 platform. 💡 𝐖𝐡𝐚𝐭’𝐬 𝐢𝐧 𝐢𝐭 𝐟𝐨𝐫 𝐲𝐨𝐮?  ✅ A comprehensive 60-marker spatial phenotyping dataset tailored to your research. ✅ Expert guidance from Akoya’s spatial biology team to supercharge your genomics and transcriptomics studies. 𝐃𝐨𝐧’𝐭 𝐰𝐚𝐢𝐭—seize this moment to push the boundaries of your research! 📅 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐃𝐞𝐚𝐝𝐥𝐢𝐧𝐞: 𝟏𝟑𝐭𝐡 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟒 Learn more and apply today! https://lnkd.in/eHJzupXd 𝐍𝐞𝐞𝐝 𝐈𝐧𝐬𝐩𝐢𝐫𝐚𝐭𝐢𝐨𝐧? Join our 𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐎𝐦𝐢𝐜𝐬 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫𝐬 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐒𝐞𝐫𝐢𝐞𝐬. Hear from leading experts in spatial biology as they share how they are integrating spatial technologies for a comprehensive, multi-analyte approach. https://lnkd.in/eZxpY2QC #SpatialProteomics #Genomics #Transcriptomics #ResearchGrant #AkoyaBiosciences

The first day of European Society for Spatial Biology is a success. We are grateful and honored to see a full-room with 300+ attendees for the presentation by Alessio Colombo. Stop by our booth to learn more about our newly launched PhenoCode IO60 panel, the mouse FFPE panel and the suite of spatial biology solutions. #ESBB #ScientificMeetings #PhenoCyclerFusion #PhenoImagerHT #PhenoCodeIO60

Exciting News in Immuno-Oncology Research! We are excited to announce that Propath UK, a leading Contract Research Organization (CRO) specializing in molecular pathology and spatial biology, and one of our qualified service providers, is the first CRO in Europe to offer the newly launched PhenoCode Discovery IO60 Panel.   This groundbreaking ultrahigh-plex panel is designed to accelerate insights and empower researchers offering a fast and comprehensive approach to immuno-oncology discovery. Propath UK's comprehensive service covers every step of the process, from expert tissue pre-processing, to staining and imaging with the Akoya Biosciences, Inc. PhenoCycler-Fusion Service, to offer a complete data analysis solution.   Come and join both Akoya Biosciences (Booth #32) and ProPath (Booth #55) at the Digital Pathology and AI Congress in London (11-12 December 2024) to learn more and explore how these innovations can elevate your research. #DigiPathLondon #TheSpatialBiologyCompany #PhenoCodeIO60 #PhenoCyclerFusion

𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐢𝐬 𝐍𝐨𝐰 𝐚 𝐑𝐞𝐚𝐥𝐢𝐭𝐲! We are excited to announce that Akoya Biosciences and NeraCare have entered into an exclusive global license agreement to develop and commercialize the groundbreaking Immunoprint Test for early-stage melanoma treatment decisions. 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬: Every year, over 235,000 new cases of melanoma are diagnosed, with 80% in early stages. These patients are often ineligible for therapies designed for advanced disease. The Immunoprint Test addresses this unmet need by identifying early-stage melanoma patients at high risk of recurrence — unlocking access to potentially life-saving treatments. 𝐖𝐡𝐚𝐭’𝐬 𝐍𝐞𝐱𝐭: By integrating Immunoprint with our market-leading PhenoImager HT platform, this partnership combines NeraCare’s innovative assay with Akoya’s cutting-edge spatial biology technology. Together, we’re driving earlier therapeutic interventions and providing tools to guide better treatment decisions for patients worldwide. 📢 𝐓𝐡𝐞 𝐞𝐫𝐚 𝐨𝐟 𝐒𝐩𝐚𝐭𝐢𝐚𝐥 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐢𝐬 𝐡𝐞𝐫𝐞 — and we’re transforming the future of melanoma care. 👉 Learn more: https://lnkd.in/gZ9Wts_z #AkoyaBiosciences #NeraCare #MelanomaCare #SpatialBiology #SpatialMedicine #Innovation #LifeSciences #Immunoprint